SCHEMBL16612115

SCHEMBL16612115

O=C(OCc1ccccc1)N1CCCCN1C(=O)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
CYP2C19 P33261 1/20 0.54
ALDH1A1 P00352 3/20 0.52
P2RX4 Q99571 2/20 0.51
HTR2C P28335 1/20 0.51
MAPK1 P28482 1/20 0.50
P2RX1 P51575 1/20 0.50
P2RX3 P56373 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSK P43235 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7279646 0.95 KMT2A (0.54) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL9354941 0.92 ALDH1A1 (0.53) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL14030742 0.92 KMT2A (0.54) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL9358225 0.91 KMT2A (0.50) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL4429871 0.89 CTSK (0.61) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL9358292 0.89 ALDH1A1 (0.53) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL3927885 0.88 CTSK (0.60) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL9358783 0.88 CTSL (0.54) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL4924522 0.88 MEN1 (0.48) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL9354322 0.87 MEN1 (0.47) KMT2AMEN1NPSR1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12103928-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2024-10-01 US disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-13 US disclosed
US-10556905-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2020-02-11 US disclosed
EP-2857401-B1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME MEIJI SEIKA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
CN-106967066-B Novel ss-lactam enzyme inhibitor and preparation method thereof 明治制果药业株式会社 2019-07-30 CN disclosed
CN-105859609-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2019-04-09 CN disclosed
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-08-17 US disclosed
CN-106967066-A New beta lactamase restrainer and preparation method thereof 明治制果药业株式会社 2017-07-21 CN disclosed
US-9708320-B2 β-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2017-07-18 US disclosed
CN-104334559-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2017-03-22 CN disclosed
CN-105859609-A Beta-lactamase inhibitor and process for preparing the same 明治制果药业株式会社 2016-08-17 CN disclosed
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-01-28 US disclosed
US-9181250-B2 Beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-11-10 US disclosed
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME MEIJI SEIKA PHARMA CO., LTD. (JP) 2015-05-21 US disclosed
EP-2857401-A1 NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME Meiji Seika Pharma Co., Ltd. (JP) 2015-04-08 EP disclosed
CN-104334559-A Novel beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO LTD 2015-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-20200048253-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-20160024090-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, MRPL21, FNTB KMT2A 2242/4885MEN1 1370/4885NPSR1 3565/4885
US-20150141401-A1 NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME ME1, FN1, FNTB KMT2A 2671/4885MEN1 1708/4885NPSR1 3433/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-12103928-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-10556905-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885
US-20170233393-A1 BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME FN1, FNTB, CPN1 KMT2A 3261/4885MEN1 550/4885NPSR1 3169/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 KMT2A 4162/4885MEN1 252/4885NPSR1 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.